Portfolio company
TenSixty Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops an artificial intelligence platform to discover tumor-selective epitopes and create antibody-based therapeutics for healthcare providers and oncology patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Nabla Bio
This company develops generative artificial intelligence and high-throughput screening platforms to design therapeutic antibodies for pharmaceutical and biotechnology partners.
Totient
This biotechnology company develops antibody therapeutics and identifies tissue-specific antigens for drug discovery using an artificial intelligence platform.
AilseBio
This biotech company develops artificial intelligence to discover therapy-induced antigens for cancer vaccines and immunotherapies for the healthcare sector.
Sift Bio
The company develops a peptide immunotherapy platform that uses artificial intelligence to identify microbial analogs for treating solid tumours in cancer patients.
Ten63 Therapeutics
This company develops small-molecule drugs for pharmaceutical partners and patients using a generative artificial intelligence and physics-based chemistry platform to treat undruggable protein targets.
Xaira
The company develops artificial intelligence platforms to design and develop antibody-based medicines for patients with various diseases.
Alceus
This company develops a platform that uses artificial intelligence to design therapeutic proteins and program immune cells for clinicians and researchers treating solid tumours.
BigHat Biosciences
BigHat Biosciences develops machine learning-designed antibody therapeutics for pharmaceutical partners and patients in oncology and immunology.
